NZ532287A - Solid pharmaceutical formulation of a piperazine urea derivative used for treating inflammatory diseases - Google Patents

Solid pharmaceutical formulation of a piperazine urea derivative used for treating inflammatory diseases

Info

Publication number
NZ532287A
NZ532287A NZ532287A NZ53228702A NZ532287A NZ 532287 A NZ532287 A NZ 532287A NZ 532287 A NZ532287 A NZ 532287A NZ 53228702 A NZ53228702 A NZ 53228702A NZ 532287 A NZ532287 A NZ 532287A
Authority
NZ
New Zealand
Prior art keywords
methyl
pharmaceutical agent
piperazine
agent formulation
formulation according
Prior art date
Application number
NZ532287A
Other languages
English (en)
Inventor
Heiko Kranz
Christoph Volkel
Ralph Lipp
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NZ532287A publication Critical patent/NZ532287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ532287A 2001-10-18 2002-10-07 Solid pharmaceutical formulation of a piperazine urea derivative used for treating inflammatory diseases NZ532287A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
PCT/EP2002/011229 WO2003035037A1 (fr) 2001-10-18 2002-10-07 Formulation pharmaceutique solide d'un derive piperazine uree

Publications (1)

Publication Number Publication Date
NZ532287A true NZ532287A (en) 2007-04-27

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ532287A NZ532287A (en) 2001-10-18 2002-10-07 Solid pharmaceutical formulation of a piperazine urea derivative used for treating inflammatory diseases

Country Status (23)

Country Link
EP (1) EP1435917A1 (fr)
JP (1) JP2005506365A (fr)
KR (1) KR20040047920A (fr)
CN (1) CN1571660A (fr)
AR (1) AR037111A1 (fr)
AU (1) AU2002333896B2 (fr)
BR (1) BR0213340A (fr)
CA (1) CA2463951A1 (fr)
CO (1) CO5580740A2 (fr)
DE (1) DE10152351B4 (fr)
EC (1) ECSP045108A (fr)
HR (1) HRP20040435A2 (fr)
IL (1) IL161166A0 (fr)
MX (1) MXPA04003522A (fr)
NO (1) NO20042022L (fr)
NZ (1) NZ532287A (fr)
PE (1) PE20030472A1 (fr)
PL (1) PL367987A1 (fr)
RS (1) RS32204A (fr)
RU (1) RU2311172C2 (fr)
UY (1) UY27500A1 (fr)
WO (1) WO2003035037A1 (fr)
ZA (1) ZA200403781B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
EP1749519A1 (fr) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Forme galénique à libération prolongée pH-indépendant pour les substances actives avec une solubilité pH-dépendante
NZ703464A (en) * 2006-04-26 2016-05-27 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
SK11262000A3 (sk) * 1998-02-05 2001-01-18 Pfizer Products Inc. Deriváty dihydroxyhexánovej kyseliny a farmaceutický prostriedok,ktorý ich obsahuje
EP1027885B1 (fr) * 1999-02-09 2008-07-09 Pfizer Products Inc. Compositions de médicaments basiques avec une meilleure biodisponibilité

Also Published As

Publication number Publication date
RS32204A (en) 2006-10-27
AR037111A1 (es) 2004-10-20
PL367987A1 (en) 2005-03-21
RU2311172C2 (ru) 2007-11-27
AU2002333896A2 (en) 2003-05-06
EP1435917A1 (fr) 2004-07-14
MXPA04003522A (es) 2004-07-23
HRP20040435A2 (en) 2005-06-30
BR0213340A (pt) 2004-10-05
DE10152351B4 (de) 2005-09-22
CA2463951A1 (fr) 2003-05-01
DE10152351A1 (de) 2003-05-08
KR20040047920A (ko) 2004-06-05
AU2002333896B2 (en) 2007-07-26
ECSP045108A (es) 2004-06-28
UY27500A1 (es) 2003-06-30
JP2005506365A (ja) 2005-03-03
WO2003035037A1 (fr) 2003-05-01
RU2004115328A (ru) 2005-06-10
ZA200403781B (en) 2004-11-29
IL161166A0 (en) 2004-08-31
CO5580740A2 (es) 2005-11-30
CN1571660A (zh) 2005-01-26
NO20042022L (no) 2004-05-14
PE20030472A1 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
JP5253381B2 (ja) シグモイド放出プロファイルを有するオキサカルバゼピンの制御放出製剤
US8007827B2 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
US7144585B1 (en) Cilostazol preparation
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
JP6588948B2 (ja) Ｃｎｓ化合物の安定化製剤
WO2009034541A9 (fr) Formes galéniques à libération contrôlée à base de trimétazidine
JP2008303223A (ja) 脈動用量薬剤経口送達システム
JP2017507928A (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
CN104755074A (zh) 美金刚的药物组合物
JP5124286B2 (ja) 徐放性製剤およびその製造方法
JP2013523757A (ja) マジンドールの製剤
AU2002333896B2 (en) Solid pharmaceutical formulation for a piperazine urea derivative
JP4022269B2 (ja) 医薬組成物
EP1287821A1 (fr) Formulations multiparticulaires d'atorvastatin calcique ayant une vitesse de libération du principe actif modulée
US20030087913A1 (en) Solid pharmaceutical agent formulation for a piperazine urea derivative
JP3929522B2 (ja) 難水溶性薬物の徐放性製剤
CZ287149B6 (en) Pharmaceutical preparation containing gemfibrozil
JP2015516971A (ja) ざ瘡の処置方法
Rhee et al. Controlled-release pelletized dosage forms using the extrusion-spheronization process
WO2007010508A2 (fr) Compositions de metaxalone a liberation controlee
US20030044459A1 (en) Biomodulated multiparticulate formulations
JP2006315971A (ja) イトラコナゾール経口投与製剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)